Abstract: A concentrated polyol composition, having a water content from 10-17%, preferably between 12 and 16%, and comprising from 35 to 90% of hydrogenated monosaccharides including at least 30% of sorbitol, and from 0 to 45% of hydrogenated disaccharides, these percentages being expressed as dry weight relative to the dry weight of all the hydrogenated saccharides contained in the said composition. This concentrated polyol composition may advantageously be unsweetened. This concentrated polyol composition may be used as a medium for dispersing hydrophilic polymers, and in particular cellulose, as well as for the preparation of pharmaceutical or cosmetological products such as toothpastes.

Abstract: The present invention provides storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred shapes of such particles are microspheres, particularly those having diameters of about 1 to about 1,000 microns. The stable shaped particles of the present invention are particularly well-suited to the fabrication of pharmaceutical formulations, particularly where sustained release and uniform bioavailability are desired. The storage stable particles are formed by a solid state crystallization of allotropic organic compounds. The solid state crystallization process of the present invention affords a means for achieving a storage stable crystalline form of said allotropic compound without loss or deterioration of the original particle dimensions.

Abstract: This invention relates to a carrier particle having a diameter of from 5 to 20 nm which contains an HDL apolipoprotein, an amphipathic lipid such as a phospholipid, and a drug which is either a hydrophobic drug, amphipathic drug, or a cationic hydrophilic drug. The carrier particle is formed by a process in which the components are co-sonicated in a buffer. The apolipoprotein is preferably apo A-I or apo A-II. The carrier particle is particularly useful for increasing plasma circulation time of a hydrophobic drug relative to conventional hydrophobic drug carrier particles. Thus, drug efficacy is improved and toxicity of the drug to renal and reticuloendothelial tissues is reduced. A composition for drug delivery comprises the carrier particle suspended in a pharmaceutically acceptable medium, and is particularly suited to administration by parenteral infusion, systemic injection, transdermal patch, oral tablet or oral spray.

Abstract: A process for manufacturing coated particles of &ggr;-aminobutyric acid analogue, whose lactam content by weight relative to the weight of &ggr;-aminobutyric acid analogue is less than 0.5% is disclosed. The process is characterized in that a coating solution of at least one polymer in an organic solvent is sprayed onto the particles of &ggr;-aminobutyric acid analogue.

Abstract: A magnetically controllable, or guided, ferrocarbon particle composition and methods of use and production are disclosed. The composition may optionally carry biologically active substances that have been adsorbed onto the particle. The composition comprises composite, volume-compounded particles of 0.1 to 5.0 &mgr;m in size, and preferably between 0.5 and 5.0 &mgr;m, containing 1.0 to 95.0% by mass of carbon, and preferably from about 20% to about 60%. The particles may be produced by mechanical milling of a mixture of iron and carbon powders. The obtained particles are optionally placed in a solution of a biologically active substance to adsorb the substance onto the particles. The composition is generally administered in suspension.

Abstract: A method of odor control in disposable, absorbent articles is provided using odor control additives comprising phosphorous-containing compounds.

Abstract: A controlled release formulation of an acetonitrile compound and its use in the treatment and/or prophylaxis of certain disorders.

Abstract: Methods for forming sustained release microspheres and the products produced thereby are provided. The microspheres have a smooth surface that includes a plurality of channel openings that are less than 1000 angstroms in diameter.

Abstract: Devices and methods for enhancing the healing of wounds, especially chronic wounds (e.g., diabetic wounds), involving the use of keratinocytes are described. Keratinocytes are grown on a transplantable solid support (e.g., collagen-coated beads), and the keratinocyte-coated solid support is placed in an enclosure. The enclosure, in turn, is placed in the wound for use as an interactive wound healing promoter.

Abstract: A composition and process for suppressing pain and irritation of tissue includes an anti-irritant in an effective amount to suppress pain and irritation temporarily when applied topically to the skin or mucosa. The anti-irritant is a natural or non-nutritive sweetener. The composition can be a solid containing an edible acid such as citric acid and ascorbic acid from fresh lemon juice to form a solution having a pH of about 2.0 to 4.0 and an anti-irritant, such as sodium saccharine. The composition can be used to apply a pharmaceutical agent to the skin, mucosa or eye without irritation. The acidic composition can further be used to remove or loosen calculus deposits from the teeth without burning or irritation of the gums.

Abstract: The invention is directed toward a malleable bone putty and a flowable gel composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing compound of demineralized lyophilized allograft bone powder. The bone powder has a particle size ranging from about 100 to about 850 microns and is mixed in a high molecular weight hydrogel carrier contain a sodium phosphate saline buffer, the hydrogel component of the carrier ranging from about 0.75 to 4.5% of the composition and having a molecular weight of about at least 160,000 Daltons. The composition has a pH between 6.8-7.4 contains about 25% to about 35% bone powder and can be additionally provided with BMP's.

Abstract: An edible, hardenable coating composition containing microcrystalline cellulose and carrageenan and either a strengthening polymer, a plasticizer or both. The coating composition of the present invention may be applied to pharmaceutical and veterinary solid dosage forms, confectionery, seeds, animal feed, fertilizers, pesticide tablets, and foods and provides an elegant prompt release coating which does not retard the release of active ingredients from the coated substrate.

Abstract: The present invention relates to a solid slow release oral pharmaceutical dosage unit resistant to amylase which comprises a solid dosage unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical agent, an optional polysaccharide or polyol, and high amylose starch, wherein the cross-linking of the high amylose starch has been carried out with a cross-linking agent with from about 0.1 g to about 40 g of cross-linking agent per 100 g of high amylose starch. In a preferred embodiment of the invention, the high amylose starch is modified with a functional group-attaching reagent that covalently bonds functional groups thereto.

Abstract: A pharmaceutical composition for oral administration contains naloxone-, N-methylnaloxone- and/or N-methylnaltrexone-containing particles which release the active substance depending on the ambient pH. This ensures the liberation of the active substance over the whole gastrointestinal tract. The side effects caused by the use of analgesic opioids, such as constipation, are thus eliminated without reducing the analgesic effect.

Abstract: A method using at least one guar gum as the sole shape-retention and/or shaping agent in cosmetic compositions intended for a temporary shaping of keratin fibres, and a method for the temporary shaping and/or deformation of keratin fibres, in particular in the shape of a hairsetting, using this compound.

Abstract: Direct compressed solid pharmaceutical dosage forms containing: a) from about 40 to about 95% by weight acetaminophen; b) from about 1 to about 60% by weight of a direct compression vehicle comprising microcrystalline cellulose; and c) from about 0.01 to about 4.0% by weight of a pharmaceutically-acceptable lubricant are disclosed. The acetaminophen and direct compression vehicle are combined under high shear conditions which are sufficient to transform acetaminophen and direct compression vehicle into a homogenous granulate without degradation. In preferred aspects of the invention, the lubricant is also combined with the acetaminophen and direct compression vehicle under high shear conditions. Methods of preparing the directly compressed solid pharmaceutical dosage forms and methods of treatment with the dosage forms are also disclosed. The methods are particularly well suited for preparing directly compressed dosage forms containing high load (i.e.

Abstract: A microbead comprising a hydrophilic matrix having active-filled microcapsules entrained therein. Compositions comprising the microbeads suspended in solution are useful for delivering active material. The microbeads of the invention may be controllable by exposing the microbeads to high or low humidity or moisture.

Abstract: The invention relates to a process for the manufacture of a pharmaceutical composition with modified release of active principle comprising at least one active principle, a lipid matrix agent composed of ester of alcohol with at least one fatty acid and at least one adjuvant. This process is characterized in that: a powder composed of at least one component selected in the group comprising the active principle and the adjuvant, is mixed, while heating and fluidizing, in order to obtain individual grains; the said lipid matrix agent is liquefied separately under warm conditions; the said powder is then coated under warm conditions by spraying the said lipid matrix agent over the individual grains; finally, the temperature of the combined product is lowered in order to allow the lipid matrix agent to solidify.

Abstract: A method of using of an aralkylalkylsiloxane includes adding the aralkylsiloxane as a component in a personal care composition, in an amount effective to enhance one or more properties, such as shine, lubricity and visual masking of inorganic components, of the personal care composition.

Abstract: A method is provided for preparing shells, concentric shells or porous, homogenous gels from alkali borate glass particles at low temperatures (i.e. room temperature or less than above 100° C.). The alkali borate glass particles contain one or more cations such as aluminum which react with an aqueous solution containing an anion such as hydroxide to form an aqueous insoluble material having a solubility limit of less than about 0.01 wt. percent. The resulting shells or gels may be used in many different applications such as a filler in resins, as filters, precursors for nano-sized powders, as thin surface films or catalyst support media. The resulting shells or gels may also have a chemotherapeutic drug added thereto, following which the resulting product is administered to a mammal and the insoluble material is dissolved form the product in vivo through administration of chelating agent.